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In this selective review, we consider a number of unsolved ques-
tions regarding the glycogen storage diseases (GSD). Thus, the 
pathogenesis of Pompe disease (GSD II) is not simply explained 
by excessive intralysosomal glycogen storage and may relate to 
a more general dysfunction of autophagy. It is not clear why de-
brancher deficiency (GSD III) causes fixed myopathy rather than 
exercise intolerance, unless this is due to the frequent accompa-
nying neuropathy. The infantile neuromuscular presentation of 
branching enzyme deficiency (GSD IV) is underdiagnosed and 
is finally getting the attention it deserves. On the other hand, the 
late-onset variant of GSD IV (adult polyglucosan body disease 
APBD) is one of several polyglucosan disorders (including La-
fora disease) due to different etiologies. We still do not under-
stand the clinical heterogeneity of McArdle disease (GSD V) or 
the molecular basis of the rare fatal infantile form. Similarly, the 
multisystemic infantile presentation of phosphofructokinase defi-
ciency (GSD VII) is a conundrum. We observed an interesting as-
sociation between phosphoglycerate kinase deficiency (GSD IX) 
and juvenile Parkinsonism, which is probably causal rather than 
casual. Also unexplained is the frequent and apparently specific 
association of phosphoglycerate mutase deficiency (GSD X) and 
tubular aggregates. By paying more attention to problems than 
to progress, we aimed to look to the future rather than to the 
past.
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Why  writing  of  glycogen  storage  diseases  (GSD), 
which are “old hats” among the metabolic disorders af-
fecting skeletal muscle? Why writing of GSD to honor 
Valerie Askanas and King Engel? Why writing with Ro-
nen Spiegel? The answer to the first question is deeply 
personal: the very first paper of the senior (chronologi-
cally, not academically) author (SDM) described a lit-
tle girl with Pompe disease (1) and his first project as a 
postdoctoral fellow with Dr. Lewis P. (Bud) Rowland was 
to unravel why glycogen accumulation is not limitless in 
muscle (2). The answer to the second question is an excit-
ing, if ancient, collaboration showing that both morpho-
logical and biochemical features of Pompe disease were 
reproduced in muscle culture (3). The answer to the third 
question is a much more recent collaboration on a pa-
tient who had phosphoglycerate kinase (PGK) deficiency 
(GSD IX) and a pure myopathy, or so we thought initially 
(see below) (4).
The truth is that GSD are still very much an open 
chapter, where new entities are discovered (5, 6), appar-
ently  paradoxical  myopathies  due  to  lack,  rather  than 
excess, of glycogen (aglycogenosis or GSD 0) are being 
reported (7, 8), old disorders, such as Lafora disease, are 
now recognized as GSD (9), and therapy based on enzyme 
replacement is reasonably successful in GSD II (10, 11).
This is not meant to be a comprehensive review of the 
muscle glycogenoses. Rather, we will consider puzzling 
aspects of some GSD, following the Roman numerical 
order shown in Figure 1.
GSD II (acid maltase deficiency, 
Pompe disease)
The first and oldest conundrum about this disorder 
was its clinical heterogeneity, with a severe generalized 
infantile  form  and  a  later-onset  form  largely  confined 
to skeletal muscle and presenting in children (juvenile 
onset)  or  in  adults  (late-onset). As  acid  maltase  (acid 
α-glucosidase, GAA) is a single ubiquitous protein, it 
is not surprising that initial findings of different residual 
GAA activities in muscle (12) have been confirmed and 
related to the severity of GAA mutations, with nonsense 
mutations prevailing in the infantile form and missense 
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and splicing (i.e. “leaky”) mutations prevailing in later 
onset cases (13, 14).
A second riddle regarded the pathogenesis of weak-
ness: was it simply due to the mechanical disarray of 
the contractile material caused by the glycogen-laden 
lysosomes or to an energy defect? The former mecha-
nistic hypothesis is questionable both because it does 
not explain the weakness of later onset GSD II and be-
cause equally disruptive overloads of lipid droplets in 
muscle were compatible with normal strength in a pre-
clinical case of neutral lipid storage disease with my-
opathy (NLSDM) (15). The latter energetic hypothesis 
is supported by the notion that GAA activity normally 
“returns” to the cytoplasm the end product of lysosomal 
glycogen digestion, glucose. It is also telling that in mus-
cle from patients with the infantile form of GSD II most 
glycogen is free in the cytoplasm, probably released by 
“burst lysosomes” (13).
A more compelling scenario for the pathogenesis of 
GSD II, as well as other lysosomal storage disorders (16), 
involves a disruption of the vital autophagic process, with 
accumulation of autophagosomes resulting from defec-
tive  autophagosome-lysosome  fusion  (16,  17).  In  fact, 
Nishino and colleagues went as far as stating that “Pompe 
disease can no longer be viewed simply as a glycogen 
storage disease,” but rather as a problem in handling ex-
cessive numbers of autophagosomes (13).
A unique feature of GSD II is the availability of a 
generally effective – and now widely utilized – enzyme 
replacement  therapy  (ERT)  with  recombinant  human 
GAA (rhGAA). There is already a vast literature on the 
subject (10), and a few problems have emerged, such as 
the immune reaction to rhGAA in infants with null muta-
tions and no GAA protein (i.e. no cross-reactive immuno-
logical material, CRIM) (18). Assumption of rhGAA into 
lysosomes is probably hindered by the more general au-
tophagic dysfunction mentioned above and several strata-
gems have been proposed to improve uptake, including 
conjugation of rhGAA with a synthetic oligosaccharide 
harboring  mannose-6-phosphate  (19),  combining  ERT 
with chaperones (20), and inhibition of glycogen synthe-
sis (21, 22).
One  final  clinical  note:  besides  skeletal  muscle, 
smooth muscle must also be affected in late-onset GSD II 
because there have been a few reports of cerebral arterio-
pathies, often affecting the basilar artery (23, 24).
GSD III (debrancher enzyme 
deficiency; Cori-Forbes disease)
The debrancher is a “double duty” enzyme, with two 
catalytic  functions,  oligo-1,4-1,4-glucantransferase  and 
amylo-1,6-glucosidase.  Once  phosphorylase  has  short-
ened  the  peripheral  chains  of  glycogen  to  about  four 
glucosyl units (this partially digested glycogen is called 
phosphorylase-limit  dextrin,  PLD),  the  debrancher  en-
zyme removes the residual stumps in two steps. First, a 
maltotriosyl unit is transferred from a donor to an accep-
tor chain (transferase activity), leaving behind a single 
glucosyl unit, which is then hydrolyzed by the amylo-1-
,6-glucosidase, at which point the branch is off. A single-
copy gene, AGL, encodes the debrancher enzyme.
A comprehensive summary of clinical features and 
therapeutic options has been published recently (25).
Considering the predominantly myopathic presenta-
tion of GSD III, a clinician would likely question why 
Figure 1. Scheme of glycogen metabolism and glyco-
lysis. Roman numerals denote muscle glycogenoses due 
to defects in the following enzymes: II, acid α-glucosidase 
(AAG); III, debrancher; IV, brancher; V, myophosphoryla-
se; VI, liver phosphorylase; VII, muscle phosphofructoki-
nase (PFK); VIII, phosphorylase b kinase (PHK); IX, phos-
phoglycerate kinase (PGK); X, phosphoglycerate mutase 
(PGAM); XI, lactate dehydrogenase (LDH); XII, aldolase; 
XIII, β-enolase; IV, triosephosphate isomerase (TPI). Sym-
bols in regular typeface denote glycogenoses character-
ized by exercise intolerance, cramps, and myoglobinuria. 
Symbols in italics denote glycogenoses characterized by 
fixed weakness.S. DiMauro, R. Spiegel
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the defect of an enzyme that acts hand-in-hand with myo-
phosphorylase should cause weakness rather than cramps 
and myoglobinuria, the clinical hallmarks of McArdle 
disease. One reason for this discrepancy may be that in 
McArdle disease glycogen cannot be metabolized at all, 
whereas in GSD III the peripheral chains of normal gly-
cogen can be utilized. However, this explanation postu-
lates that the intact glycogenosynthetic pathway allows 
some turnover between normal glycogen and PLD, which 
is not unreasonable.
Another explanation for the fixed and mostly dis-
tal weakness of patients with GSD III (26) is the si-
multaneous  involvement  of  muscle  and  nerve,  as 
documented both electrophysiologically and by nerve 
biopsy (27, 28).
GSD IV (branching enzyme 
deficiency, Andersen disease)
The glycogen branching enzyme (GBE) is a single 
polypeptide encoded by one gene (GBE1). GBE deficien-
cy results in the deposit of an amylopectin-like polysac-
charide that has fewer branching points and longer outer 
chains than normal glycogen and is known as polyglu-
cosan.  Polyglucosan  is  periodate/Schiff  (PAS)-positive 
and only partially digested by diastase, which makes it 
easily recognizable in various tissues and offers an im-
portant clue to the correct diagnosis.
It is gratifying to see that in the just published 22nd 
edition of Rudolph’s Pediatrics, the neuromuscular pres-
entation of GSD IV is given as much space as the hepatic 
form (29), which dominated previous textbook descrip-
tions.
In fact, the neuromuscular presentation has been un-
derdiagnosed, judging from the flurry of recent papers. 
As recognized in a seminal paper of 2004 (30), there are 
two main infantile presentations. The first is a perinatal 
disorder known as “fetal akinesia deformation sequence” 
or FADS, characterized by multiple congenital contrac-
tures (arthrogryposis multiplex congenita), hydrops fe-
talis, pulmonary hypoplasia, craniofacial abnormalities, 
intrauterine retarded growth (IURG), abnormal amniotic 
fluid volume, and perinatal death. The second, labeled 
“congenital,” should probably be called “fatal infantile,” 
as it presents at or soon after birth with hypotonia, muscle 
wasting,  neuronal  involvement,  inconsistent  cardiomy-
opathy, and early death.
Detailed  neuropathology  in  a  girl  who  died  at  3 
months showed PAS-positive polyglucosan inclusions in 
neurons of basal ganglia and thalamus, oculomotor and 
pontine nuclei, and in periaqueductal neurons (31). In 
the medulla, polyglucosan deposits were noted in the hy-
poglossal nucleus, the dorsal motor nucleus of the vagus, 
and the nucleus ambiguus. Similar findings were reported 
in two more infants (32, 33). The motor neurons of the 
spinal cord are also severely affected (32), explaining how 
one of the patients we studied was initially diagnosed as 
spinal muscular atrophy type I (SMA I) until mutations in 
the SMN1 gene were ruled out (34).
At the other end of the clinical spectrum, there is 
adult polyglucosan body disease (APBD), a neurological 
variant of GSD IV presenting late in life with progres-
sive upper and lower motor neuron dysfunction (simu-
lating amyotrophic lateral sclerosis), sensory neuropathy, 
neurogenic bladder (APBD patients often see a urolo-
gist before they see a neurologist), and – in about 50% 
of patients – dementia. The disease predominates among 
people of Askenazi Jewish descent (probably due to a 
founder effect) and is most commonly due to the Y329S 
mutation in GBE1. Not too surprisingly, this is a “mild” 
mutation,  which  probably  explains  the  late  onset  of 
symptoms. Thanks to the energy and compassion of one 
patient, Gregory Weiss, a research foundation (APBDRF; 
www.apbdrf.org) has been created to develop therapeutic 
strategies.
GSD V (myophosphorylase 
deficiency, McArdle disease)
The clinical picture and the block in muscle glycogen 
breakdown were elegantly described by Brian McArdle 
in 1951 (35), the enzyme defects was discovered 8 years 
later (36-38), and it took 12 more years before the first 
mutations in PYGM were identified (39).
Despite its long history, McArdle disease still presents 
several riddles. First, although it was long considered a 
clinically homogeneous disease, its expression can vary 
from relatively mild exercise intolerance to a crippling 
condition with frequent cramps and recurrent episodes of 
myoglobinuria. Explanations have ranged from rare cases 
of “double trouble” (i.e. the coexistence in the same indi-
viduals of one mutation in PYGM and another in the gene 
encoding adenylate deaminase) to the association with 
insertion/deletion  polymorphisms  in  the  angiotensin-
converting enzyme (ACE) (40). Probably more important 
is the protecting effect of even small amounts of myo-
phosphorylase residual activity, which is determined by 
the type of mutations: for example, splice mutations are 
associated to milder clinical phenotypes (41).
What remains unexplained is the fatal infantile form 
of McArdle disease, which has been reported in a handful 
of cases (42-45). In these unfortunate infants muscle mor-
phology, biochemistry, and molecular genetics [showing 
the “common” R50X null mutation (39, 45)] are no dif-
ferent from typical McArdle patients, despite the dismal 
outcome.Progress and problems in muscle glycogenoses
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GSD VII (phosphofructokinase 
[PFK] deficiency, Tarui disease)
PFK is a tetrameric enzyme under the control of three 
autosomal  genes:  PFKM  encodes  the  muscle  subunit, 
PFKL encodes the liver subunit, and PFKP encodes the 
platelet subunit. Mature human muscle expresses only the 
M subunit and contains exclusively the M4 homotetram-
er, whereas erythrocytes, which express both the M and 
the L subunit, contain five isozymes, the two M4 and L4 
homotetramers and three hybrid forms. In patients with 
typical PFK deficiency, mutations in PFKM cause total 
lack of activity in muscle but only partial deficiency in 
red blood cells.
Clinically, PFK deficiency, first described in 1965 in a 
Japanese family (46), is indistinguishable from McArdle 
disease, except for the absence of a typical second wind 
phenomenon and for the occasional presence of gouty ar-
thritis due to “myogenic hyperuricemia” (47).
Two peculiar aspects of GSD VII are worth discuss-
ing: the presence of polyglucosan in muscle and the se-
vere infantile presentation.
The presence – in addition to normal-looking glyco-
gen – also of abnormal glycogen with the histochemical 
(diastase-resistance) and ultrastructural (fine granules and 
filaments instead of β-particles) features of polyglucosan 
was first noted in the muscle biopsy of two patients (48) 
and confirmed in a woman who had developed late-onset 
fixed  weakness  (49). We  reasoned  that  this  surprising 
finding could best be explained by the excessive accu-
mulation of glucose-6-phosphate (G6P) upstream of the 
glycolytic block (49). As G6P is a functional activator of 
glycogen synthetase (GS), the finely balanced activity ra-
tio of GS and GBE would be tilted in favor of GS and re-
sult in a polysaccharide with abnormally long and poorly 
branched chains, i.e. polyglucosan.
This pathogenic concept was confirmed by two experi-
ments, one in the laboratory, the other an experiment of na-
ture. First, when Nina Raben upregulated the expression of 
GS in the muscle of GAA-deficient mice, she unexpectedly 
obtained polyglucosan accumulation (50). Second, after a 
long search for the molecular basis of polyglucosan my-
opathy in horses, Stephanie Valberg and co-workers identi-
fied a gain-of-function mutation in GS, again altering the 
GS/GBE activity ratio in favor of GS (5).
The second riddle concerns the fatal infantile variant 
of GSD VII, reported in a dozen patients between 1987 
and 2008. All infants were severely hypotonic at birth and 
a few developed joint contractures either in utero (51-53) 
or postnatally (54, 55). Decreased fetal movements were 
noted in two pregnancies (52, 53) and polyhydramnios in 
one (53). In all but two cases (53, 55), death occurred in 
infancy or early childhood due to pulmonary failure.
Most children showed evidence of multisystem in-
volvent, including seizures, cortical blindness, develop-
mental delay, dysmorphic features, and corneal ulcers. 
The encephalopathy was documented by neuroradiology 
or neuropathology, which showed dilated ventricles and 
cortical or cerebellar atrophy (51, 54-57).
Because of the early onset, multisystem involvement, 
and lack of any molecular evidence of mutations in the 
PFKM gene, the infantile variant of phosphofructokinase 
deficiency appears to be a separate entity from GSD VII, 
and its genetic basis (or bases) remain to be clarified, de-
spite evidence that a transgenic PFKM-null mouse mim-
ics the infantile more than the typical muscular form of 
the human disease (58).
GSD VIII (Phosphorylase b kinase 
[PHK] deficiency)
PHK is a multimeric enzyme composed of four dif-
ferent subunits, α, β, γ, and δ and the enzyme composi-
tion is (αβγδ)4. The γ subunit is catalytic and is regulated 
by the degree of phosphorylation of the α and β subunits. 
Calcium sensitivity is conferred by the δ subunit, which 
is tightly bound to calmodulin.
PHK deficiency has been associated with five main 
syndromes distinguished by inheritance and by tissue in-
volvement: (i) a benign X-linked recessive hepatopathy 
of infancy or childhood (59); (ii) an autosomal recessive 
liver and muscle disease (60); (iii) a pure myopathy pre-
dominant in men (61); (iv) an autosomal recessive severe 
liver disease with cirrhosis (62); and (v) a fetal infantile 
cardiopathy, reported in a handful of patients (63-68).
The pure myopathy has thus far been described in 
detail only in men and is due to mutations in the X-linked 
gene  (PHKA1)  encoding  the  muscle-specific  α  subu-
nit (69-73). Not surprisingly, patients with PHK deficien-
cy have a clinical picture resembling McArdle disease, 
except much milder, a sort of “McArdle light.” For ex-
ample, patients usually have normal venous lactate rise 
after forearm ischemic exercise, no evidence of second 
wind, and modest accumulation of glycogen in the mus-
cle biopsy. Formal cycle ergometry studies confirmed the 
mild impairment of glycogenolysis: there was no change 
in lactate during dynamic, submaximal exercise and IV 
glucose administration improved exercise tolerance, but 
less than in McArdle patients (72).
The  molecular  basis  underlying  the  fatal  infantile 
cardiomyopathy has been a puzzle for many years be-
cause there is no heart-specific PHK isozyme. The rid-
dle was solved when Burwinkel et al. definitely excluded 
mutations in any of the PHK genes (74) but detected a 
single dominant mutation in the gene (PRKAG2) encod-
ing the γ2 subunit of the AMP-activated protein kinase S. DiMauro, R. Spiegel
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(AMPK). Later, we identified a second mutation in an-
other infant (75). AMPK is an αβγ heterotrimer function-
ing as a “cellular fuel gauge,” which is switched on by 
increases in the AMP:ATP ratio, an indicator of cellular 
energy deficit (76.
What remains a mystery is why mutations in AMPK 
should inhibit PHK and cause a “pseudo-PHK deficien-
cy.” We suspect that a similar mechanism may operate 
in the fatal infantile PFK deficiency that we discussed 
above.
GSD IX (phosphoglycerate kinase 
[PGK] deficiency)
PGK is a single polypeptide encoded by a gene 
(PGK1)  on  Xq13  and  present  in  all  tissues  except 
spermatogenic cells. Although this enzyme is virtually 
ubiquitous, clinical presentations depend on the iso-
lated or combined involvement of three tissues: eryth-
rocytes (hemolytic anemia), skeletal muscle (exercise 
intolerance, cramps, myoglobinuria), and the central 
nervous  system  ([CNS]  seizures,  mental  retardation, 
stroke).
In a recent review (4), we found that the most com-
mon association, seen in 11 of 33 patients (34%) was 
hemolytic anemia and CNS involvement. Isolated myop-
athy was a close second (9 of 33 patients, 27%). Isolated 
blood dyscrasia was reported in 6 patients (18%), the as-
sociation of myopathy and CNS dysfunction in 4 patients 
(12%), the association of anemia and myopathy only in 
one patient (3%), and the involvement of all three tissues 
in 2 patients (6%).
However, the plot thickened when we found yet an-
other patient with the association of myopathy and a pecu-
liar CNS dysfunction, namely, severe juvenile Parkinson-
ism (77). What we found strange and a little disconcerting 
was that this young man harbored the same previously 
unreported mutation (p.T378P) that we had identified in 
our latest patient with pure myopathy (4). However, we 
recovered some confidence in genotype:phenotype cor-
relation when Dr. Spiegel’s patient also developed severe 
Parkinsonian symptoms and signs. Although this is an n 
of 2 series, our findings raise two interesting questions. 
First, is there, in fact, a causal relationship between the 
T378P mutation and Parkinsonism? Second, PGK defi-
ciency was suspected in both patients because they pre-
sented  initially  with  exercise  intolerance,  cramps,  and 
myoglobinuria:  Parkinsonism  was  a  surprising  clinical 
development.  One  cannot  help  wondering  whether  in 
some patients with PGK deficiency juvenile Parkinson 
disease may precede and overshadow the myopathy, thus 
escaping diagnosis. Certainly, this association has to be 
kept in mind.
GSD X (phosphoglycerate mutase 
[PGAM] deficiency)
PGAM is a dimeric enzyme composed of a muscle-
specific  (M)  subunit  and  a  brain-specific  (B)  subunit. 
Normal adult human muscle contains predominantly the 
MM homodimer, which accounts for about 95% of the 
total activity.
Fourteen patients with PGAM deficiency in muscle 
have been reported, of whom nine were African Ameri-
can (78, 79). Although the first reported patient could not 
be studied at the molecular level (80), all other African 
American patients harbored the W78X mutation, at least 
in heterozygosity, suggesting a founder effect.
The most striking peculiarity of GSD X is its common 
association with tubular aggregates (TAs), which were 
seen in the muscle biopsies of 5 patients (36%) whereas 
they have never been reported in other glycogenoses. TAs 
are ordered stacks of tubules originating from the sarco-
plasmic reticulum. Although they are a nonspecific patho-
logical change seen in diverse conditions, including expo-
sure to drugs, toxins, and hypoxia, their association with 
PGAM deficiency does not appear to be casual although 
the specific trigger remains unknown.
Conclusions
As stated at the outset, we did not intend to review 
all the muscle glycogenoses, but only to consider some 
conundrums still presented by “old” GSD. We have not 
considered Lafora disease because muscle involvement is 
overshadowed by the devastating encephalopathy. Like-
wise,  we  have  not  discussed  some  recently  described 
glycogenoses, such as aldolase deficiency (81), β-enolase 
deficiency (82), and the two forms of glycogenosis type 0 
(aglycogenosis?) (7, 8) because they have been described 
in single patients.
Thus, although we discussed more the problems than 
the progress promised in the title, we hope our considera-
tions are an adequate homage to Valerie Askanas and W. 
King Engel.
References
1.  Favini Sacerdoti F, DiMauro S, Angelini Dobrilla C. Un caso di 
glicogenosi tipo II (m. di Pompe). Studio clinico, morfologico e 
biochimico. Acta Paediatr Latina 1967;20:651-77.
2.  DiMauro S, Rowland LP, DiMauro PM. Control of glycogen me-
tabolism in human muscle. Arch Neurol 1970;23:534-40.
3.  Askanas V, Engel WK, DiMauro S et al. Adult-onset acid maltase 
deficiency.  Morphological  and  biochemical  abnormalities  repro-
duced in cultured muscle. New Engl J Med 1976;294:573-8.
4.  Spiegel R, Area Gomez E, Akman HO, et al. Myopathic form of 
phosphoglycerate kinase (PGK) deficiency: A new case and patho-
genic considerations. Neuromusc Disord 2009;19:207-11.Progress and problems in muscle glycogenoses
101
26.  DiMauro S, Hartwig GB, Hays AP, et al. Debrancher deficiency: 
neuromuscular disorder in five adults. Ann Neurol 1979;5:422-36.
27.  Powell HC, Haas R, Hall CL, et al. Peripheral nerve in type III gly-
cogenosis: selective involvement of unmyelinated fiber Schwann 
cells. Muscle Nerve 1985;8:667-71.
28.  Ugawa Y, Inoue K, Takemura T, et al. Accumulation of glycogen in 
sural nerve axons in adult-onset type III glycogenosis. Ann Neurol 
1986;19:294-7.
29.  Kishnani P, Chen Y-T. Disorders of glycogen metabolism. In: Ru-
dolph CD, Rudolph AM, Lister GE, et al., eds. Rudolph’s Pediat-
rics. 22nd ed. New York: McGraw Hill 2011, pp. 599-607.
30.  Bruno C, van Diggelen OP, Cassandrini D, et al. Clinical and ge-
netic heterogeneity of branching enzyme deficiency (glycogenosis 
type IV). Neurology 2004;63:1053-8.
31.  Taratuto AL, Akman HO, Saccoliti M, et al. Branching enzyme de-
ficiency/glycogenosis storage disease type IV presenting as a severe 
congenital hypotonia: Muscle biopsy and autopsy findings, biochem-
ical and molecular studies. Neuromusc Dis 2010;20:783-90.
32.  Herrick MK, Twiss JL, Vladutiu GD, et al. Concomitant branching 
enzyme and phosphorylase deficiencies. An unusual glycogenosis 
with extensive neuronal polyglucosan storage. J. Neuropath Exp 
Neurol 1994;53:239-46.
33.  Konstantinidou AE, Anninos  H,  Gyftodimou Y,  et  al.  Neonatal 
neuromuscular variant of glycogen storage disease type IV: his-
topathological findings leading to the diagnosis. Histopathology 
2006;48:878-80.
34.  Tay SKH, Akman HO, Chung WK, et al. Fatal infantile neuromus-
cular presentation of glycogen storage disease type IV. Neuromusc 
Disord 2004;14:253-60.
35.  McArdle B. Myopathy due to a defect in muscle glycogen break-
down. Clin Sci 1951;10:13-33.
36.  Schmidt R, Mahler R. Chronic progressive myopathy with my-
oglobinuria: demonstration of a glycogenolytic defect in the mus-
cle. J Clin Invest 1959;38:2044-58.
37.  Mommaerts W, Illingworth B, Pearson CM, et al. A functional dis-
order of muscle associated with the absence of phosphorylase. Proc 
Nat Acad Sci U S A 1959;45:791-7.
38.  Larner J, Villar-Palasi C. Enzymes in a glycogen-storage myopathy. 
Proc Nat Acad Sci U S A 1959;45:1234-5.
39.  Tsujino S, Shanske S, DiMauro S. Molecular genetic heterogeneity 
of myophosphorylase deficiency (McArdle’s disease). New Engl J 
Med 1993;329:241-5.
40.  Martinuzzi A, Sartori E, Fanin M, et al. Phenotype modulators in 
myophosphorylase deficiency. Ann Neurol 2003;53:497-502.
41.  Vissing J, Duno M, Schwartz M, et al. Splice mutations preserve 
myophosphorylase  activity  that  ameliorates  the  phenotype  in 
McArdle disease. Brain 2009;132:1545-52.
42.  DiMauro S, Hartlage P. Fatal infantile form of muscle phosphory-
lase deficiency. Neurology 1978;28:1124-9.
43.  Miranda AF, Nette G, Hartlage P, et al. Phosphorylase isoenzymes 
in normal and myophosphorylase deficient human heart. Neurology 
1979;29:1538-41.
44.  Milstein JM, Herron TM, Haas JE. Fatal infantile muscle phospho-
rylase deficiency. J Child Neurol 1989;4:186-8.
45.  El-Schahawi M, Bruno C, Tsujino S, et al. Sudden infant death 
syndrome (SIDS) in a family with myophosphorylase deficiency. 
Neuromusc Disord 1997;7:81-3.
46.  Tarui S, Okuno G, Ikua Y, et al. Phosphofructokinase deficiency in 
skeletal muscle. A new type of glycogenosis. Biochem Biophys Res 
Comm 1965;19:517-23.
5.  McCue  ME,  Valberg  SJ,  Miller  MB  et  al.  Glycogen  synthase 
(GYS1) mutation causes a novel skeletal muscle glycogenosis. Ge-
nomics 2008;91:458-66.
6.  Stojkovic T, Vissing J, Petit F, et al. Muscle glycogenosis due to phos-
phoglucomutase 1 deficiency. New Engl J Med 2009;361:425-7.
7.  Kollberg G, Tulinius M, Gilljam T, et al. Cardiomyopathy and exer-
cise intolerance in muscle glycogen storage disease 0. New Engl J 
Med 2007;357:1507-14.
8.  Moslemi A-R, Lindberg C, Nilsson J, et al. Glycogenin-1 deficien-
cy and inactivated priming of glycogen synthesis. New Engl J Med 
2010;362:1203-10.
9.  Turnbull  J,  Wang  P,  Girard  J-M,  et  al.  Glycogen  hyperphos-
phorylation  underlies  Lafora  body  formation.  Ann  Neurol 
2010;68:925-33.
10.  van der Ploeg AT. Where do we stand in enzyme replacement ther-
apy in Pompe’s disease? Neuromusc Dis 2010;20:733-4.
11.  van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study 
of alglucosidase alfa in late-onset Pompe’s disease. New Engl J 
Med 2010;362:1396-406.
12.  Mehler M, DiMauro S. Residual acid maltase activity in late-onset 
acid maltase deficiency. Neurology 1977;27:178-84.
13.  Malicdan MC, Noguchi S, Nonaka I, et al. Lysosomal myopathies: 
An excessive build-up in autophagosomes is too much to handle. 
Neuromusc Disord 2008;18:521-9.
14.  Nascimbeni AC, Fanin M, Tasca E, et al. Molecular pathology and 
enzyme processing in various phenotypes of acid maltase deficien-
cy. Neurology 2008;70:617-26.
15.  Akman HO, Davidzon G, Tanji K, et al. Neutral lipid storage dis-
ease with subclinical myopathy due to a retrotransposal insertion in 
the PNPLA2 gene. Neuromusc Dis 2010;20:397-402.
16.  Settembre C, Fraldi A, Jahreiss L, et al. A block of autophagy in 
lysosomal storage disorders. Hum Mol Genet 2008;17:119-29.
17.  Fukuda T, Ewan L, Bauer M, et al. Dysfunction of endocytic and 
autophagic pathways in a lysosomal storage disease. Ann Neurol 
2006;59:700-8.
18.  Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reacting 
immunological material status affects treatment outcomes in Pompe 
disease infants. Mol Genet Metab 2010;99:26-33.
19.  Zhu Y, Jiang J-L, Gumlaw NK, et al. Glycoengineered acid alpha-
glucosidase with improved efficacy at correcting the metabolic ab-
errations and motor function deficits in a mouse model of Pompe 
disease. Mol Ther 2009;17:954-63.
20.  Parenti  G.  Treating  lysosomal  storage  diseases  with  pharmaco-
logical  chaperones:  from  concept  to  clinics.  EMBO  Mol  Med 
2009;1:268-79.
21.  Douillard-Guilloux G, Raben N, Takikita S, et al. Restauration of 
muscle functionality by genetic suppression of glycogen synthesis in 
a murine model of Pompe disease. Hum Mol Genet 2010;19:684-96.
22.  Ashe KM, Taylor KM, Chu Q, et al. Inhibition of glycogen biosyn-
thesis via mTORC1 suppression as an adjunct therapy for Pompe 
disease. Mol Genet Metab 2010;100:309-15.
23.  Laforet P, Petiot P, Nicolino M, et al. Dilative arteriopathy and basi-
lar artery dolichoectasia complicating late-onset Pompe disease. 
Neurology 2008;70:2063-6.
24.  Sacconi S, Bocquet JD, Chanalet S, et al. Abnormalities of cerebral 
arteries are frequent in patients with late-onset Pompe disease. J. 
Neurol 2010;257:1730-3.
25.  Kishnani P, Austin SL, Arn P, et al. Glycogen storage disease 
type  III  diagnosis  and  management  guidelines.  Genet  Med 
2010;12:446-63.S. DiMauro, R. Spiegel
102
65.  Elleder M, Shin YS, Zuntova A, et al. Fatal infantile hypertrophic 
cardiomyopathy secondary to deficiency of hert specific phospho-
rylase b kinase. Virchows Arch A 1993;423:303-7.
66.  Regalado JJ, Rodriguez MM, Ferrer PL. Infantile hypertrophic car-
diomyopathy of glycogenosis type IX: isolated cardiac phosphory-
lase kinase deficiency. Pediatr Cardiol 1999;20:304-7.
67.  Buhrer  C,  van  Landeghem  FKH,  Felderhoff-Mueser  U,  et  al. 
Fetal bradycardia at 28 weeks of gestation associated with car-
diac  glycogen  phosphorylase  b  kinase  deficiency. Acta  Paediatr 
2003;92:1352-3.
68.  Eishi Y,  Takemura  T,  Sone  R,  et  al.  Glycogen  storage  disease 
confined to the heart with deficient activity of cardiac phosphory-
lase kinase: a new type of glycogen storage disease. Hum Pathol 
1985;16:193-7.
69.  Bruno C, Manfredi G, Andreu AL, et al. A splice junction muta-
tion in the alpha-M gene of phosphorylase kinase in a patient with 
myopathy. Biochem Biophys Res Comm 1998;249:648-51.
70.  Wehner M, Clemens PR, Engel AG, et al. Human muscle glycog-
enosis due to phosphorylase kinase deficiency associated with a 
nonsense mutation in the muscle isoform of the alpha subunit. Hum 
Mol Genet 1994;3:1983-7.
71.  Wuyts W, Reyniers E, Ceuterick C, et al. Myopathy and phospho-
rylase kinase deficiency caused by a mutation in the PHKA1 gene. 
Am J Med Genet 2005;133A:82-4.
72.  Orngreen MC, Schehaas HJ, Jeppesen TD, et al. Is muscle glycog-
enolysis impaired in X-linked phosphorylase b kinase deficiency? 
Neurology 2008;70:1876-82.
73.  Echaniz-Laguna A, Akman HO, Mohr M, et al. Muscle phospho-
rylase  b  kinase  deficiency  revisited.  Neuromusc  Disord  2010; 
20:125-7.
74.  Burwinkel B, Hu B, Schroers A, et al. Muscle glycogenosis with 
low phosphorylase kinase activity: mutations in PHKA1, PHKG1 
or six other candidate genes explain only a minority of cases. Eur J 
Hum Genet 2003;11:516-26.
75.  Akman HO, Sampayo JN, Ross FA, et al. Fatal infantile cardiac 
glycogenosis with phosphorylase kinase deficiency and a mutation 
in the gamma2-subunit of AMP-activated protein kinase. Pediatr 
Res 2007;62:499-504.
76.  Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase – 
development of the energy sensor concept. J Physiol 2006;574:7-15.
77.  Sotiriou E, Greene P, Krishna S, et al. Myopathy and Parkinsonism in 
phosphoglycerate kinase deficiency. Muscle Nerve 2010;41:707-10.
78.  Tonin P, Bruno C, Cassandrini D, et al. Unusual presentation of 
phosphoglycerate mutase deficiency due to two different mutations 
in PGAM-M gene. Neuromusc Disord 2009;19:776-8.
79.  Naini A, Toscano A, Musumeci O, et al. Muscle phosphoglycerate 
mutase deficiency revisited. Arch Neurol 2009;66:394-8.
80.  DiMauro  S,  Miranda AF,  Khan  S,  et  al.  Human  muscle  phos-
phoglycerate mutase deficiency: newly discovered metabolic my-
opathy. Science 1981;212:1277-9.
81.  Kreuder J, Borkhardt A, Repp R, et al. Inherited metabolic myopa-
thy and hemolysis due to a mutation in aldolase A. New Engl J Med 
1996;334:1100-4.
82.  Comi GP, Fortunato F, Lucchiari S, et al. B-enolase deficiency, 
a  new  metabolic  myopathy  of  distal  glycolysis.  Ann  Neurol 
2001;50:202-7.
47.  Mineo I, Kono N, Hara N, et al. Myogenic hyperuricemia. A com-
mon pathophysiologic feature of glycogenosis types III, V, and VII. 
New Engl J Med 1987;317:75-80.
48.  Agamanolis DP, Askari AD, DiMauro S, et al. Muscle phosphof-
ructokinase  deficiency:  Two  cases  with  unusual  polysaccharide 
accumulation and immunologically active enzyme protein. Muscle 
Nerve 1980;3:456-67.
49.  Hays AP, Hallett M, Delfs J, et al. Muscle phosphofructokinase de-
ficiency: abnormal polysaccharide in a case of late-onset myopathy. 
Neurology 1981;31:1077-86.
50.  Raben N, Danon MJ, Lu N, et al. Surprises of genetic engineer-
ing: a possible model of polyglucosan body disease. Neurology 
2001;56:1739-45.
51.  Moerman P, Lammens M, Fryns JP, et al. Fetal akinesia sequence 
caused by glycogenosis type VII. Genet. Couns 1995;6:15-20.
52.  Swoboda KJ, Specht L, Jones HR, et al. Infantile phosphofructoki-
nase deficiency with arthrogryposis: Clinical benefit of a ketogenic 
diet. J. Pediatr 1997;131:932-4.
53.  Spriggs EL, Marles SL, Lacson A, et al. Long-term survival and 
normal cognitive development in infantile phosphofructokinase-1 
deficiency. Clin Genet 1999;56:235-7.
54.  Danon MJ, Carpenter S, Manaligod JR, et al. Fatal infantile glyco-
gen storage disease: Deficiency of phosphofructokinase and phos-
phorylase b kinase. Neurology 1981;31:1303-7.
55.  Al-Hassnan ZN, Al Budhaim M, Al-Owain M, et al. Muscle phos-
phofructokinase deficiency with neonatal seizures and nonprogres-
sive course. J. Child Neurol 2007;22:106-8.
56.  Servidei  S,  Bonilla  E,  Diedrich  RG,  et  al.  Fatal  infantile 
form  of  muscle  phosphofructokinase  deficiency.  Neurology 
1986;36:1465-70.
57.  Pastoris O, Dossena M, Vercesi L, et al. Muscle phosphofructoki-
nase deficiency in a myopathic child with severe mental retardation 
and aplasia of cerebellar vermis. Child Nerv Syst 1992;8:237-41.
58.  Garcia M, Pujol A, Ruzo A, et al. Phosphofructo-1-kinase deficien-
cy leads to severe cardiac and hematological disorder in addition to 
skeletal muscle glycogenosis. PLoS Genet 2009;5:e1000615.
59.  Hendrickx J, Lee P, Keating J, et al. Complete genomic structure 
and mutational spectrum of PHKA2 in patients with X-linked liver 
glycogenosis type I and II. Am J Hum Genet 1999;64:1541-9.
60.  Burwinkel B, Maichele AJ, Aagenaes O, et al. Autosomal glycog-
enosis of liver and muscle due to phosphorylase kinase deficiency 
is caused by mutations in the phosphorylase kinase beta subunit 
(PHKB). Hum Mol Genet 1997;6:1109-15.
61.  Wilkinson DA, Tonin P, Shanske S, et al. Clinical and biochemi-
cal features of 10 adult patients with muscle phosphorylase kinase 
deficiency. Neurology 1994;44:461-6.
62.  Kilimann MW. Glycogen storage disease due to phosphorylase ki-
nase deficiency. In: Swallow DM, Edwards YH, eds. Protein dys-
function in human genetic disease. Oxford: Bios Scientific Publish-
ers 1997, pp. 57-75.
63.  Mizuta K, Hashimoto E, Tsutou A, et al. A new type of glycogen 
storage disease caused by deficiency of cardiac phosphorylase ki-
nase. Biochem Biophys Res Commun 1984;119:582-7.
64.  Servidei  S,  Metlay  LA,  Chodosh  J,  et  al.  Fatal  infantile  car-
diopathy caused by phosphorylase b kinase deficiency. J Pediat 
1988;113:82-5.